Activity and diffusion of tigecycline (GAR-936) in experimental enterococcal endocarditis

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 1, 2003, Pages 216-222

  Lefort, Agnès ^d,e   Lafaurie, Matthieu ^d,e   Massias, Laurent ^a   Petegnief, Yolande ^b,e   Saleh Mghir, Azzam ^d,e   Muller Serieys, Claudette ^c   Le Guludec, Dominique ^b,e   Fantin, Bruno ^d,e,f  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^b Serv Med Nucl   (France)

^c Service de Microbiologie   (France)

^d BICHAT HOSPITAL   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f BEAUJON HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; GLYCOPEPTIDE; MINOCYCLINE; TEICOPLANIN; TETRACYCLINE; TIGECYCLINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COUNT; BACTERIAL ENDOCARDITIS; BACTERIOSTASIS; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DIFFUSION; DRUG HALF LIFE; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; EXPERIMENTAL INFECTION; FEMALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POSTANTIBIOTIC EFFECT; PRIORITY JOURNAL; RABBIT;

ANIMALS; AREA UNDER CURVE; AUTORADIOGRAPHY; ENDOCARDITIS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; HALF-LIFE; METABOLIC CLEARANCE RATE; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; RABBITS; TISSUE DISTRIBUTION;

EID: 12244262303     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.1.216-222.2003     Document Type: Article

References (18)

1. Arthur, M., F. Depardieu, G. Gerbaud, M. Galimand, R. Leclercq, and P. Courvalin. 1997. The VanS sensor negatively controls VanR-mediated transcriptional activation of glycopeptide resistance genes of Tn1546 and related elements in the absence of induction. J. Bacteriol. 179:97-106.
2. Boucher, H. W., C. B. Wennersten, and G. M. Eliopoulos. 2000. In vitro activities of the glycylcydine GAR-936 against gram-positive bacteria. Antimicrob. Agents Chemother. 44:2225-2229.
3. Craig, W. A., and S. Gudmundsson. 1996. Postantibiotic effect, p. 296-329. In V. Lorian (ed.), Antibiotics in laboratory medicine, 4th ed. Williams and Wilkins, Baltimore, Md.
4. Englert, D., N. Roessler, A. Jeavons, and S. Fairless. 1995. Microchannel array detector for quantitative electronic radioautography. Cell. Mol. Biol. (Noisy-le-grand) 41:57-64.
5. Gales, A. C., and R. N. Jones. 2000. Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates. Diagn. Microbiol. Infect. Dis. 36:19-36.
6. Goldstein, E. J., D. M. Citron, C. V. Merriam, Y. Warren, and K. Tyrrell. 2000. Comparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens. Antimicrob. Agents Chemother. 44:2747-2751.
7. Jacob, A. E., and S. J. Hobbs. 1974. Conjugal transfer of plasmid-borne multiple antibiotic resistance in Streptococcus faecalis var. zymogenes. J. Bacteriol. 117:360-372.
8. Jones, R. N. 1999. Disk diffusion susceptibility test development for the new glycylcycline, GAR-936. Diagn. Microbiol. Infect. Dis. 35:249-252.
9. Leclercq, R. 1997. Enterococci acquire new kinds of resistance. Clin. Infect. Dis. 24(Suppl. 1):80-84.
10. Lefort, A., and B. Fantin. 1999. Rabbit model of bacterial endocarditis, p. 611-617. In O. Zak and M. Sande (ed.), Handbook of animal models of infection. Academic Press, London, United Kingdom.
11. Murphy, T. M., J. M. Deitz, P. J. Petersen, S. M. Mikels, and W. J. Weiss. 2000. Therapeutic efficacy of GAR-936, a novel glycylcycline, in a rat model of experimental endocarditis. Antimicrob. Agents Chemother. 44:3022-3027.
12. Patel, R., M. S. Rouse, K. E. Piper, and J. M. Steckelberg. 2000. In vitro activity of GAR-936 against vancomycin-resistant enterococci, methicillinresistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae. Diagn. Microbiol. Infect. Dis. 38:177-179.
13. Petersen, P. J., N. V. Jacobus, W. J. Weiss, P. E. Sum, and R. T. Testa. 1999. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob. Agents Chemother. 43:738-744.
14. Projan, S. J. 2000. Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent. Pharmacotherapy 20:219S-223S.
15. Saleh-Mghir, A., A. Lefort, Y. Petegnief, S. Dautrey, J. M. Vallois, D. Le Guludec, C. Carbon, and B. Fantin. 1999. Activity and diffusion of LY333328 in experimental endocarditis due to vancomycin-resistant Enterococcus faecalis. Antimicrob. Agents Chemother. 43:115-120.
16. Steel, R. G. D., and J. H. Tovrie. 1980. Multiple comparisons, p. 172-194. In C. Napier and J. W. Maisel (ed.), Principles and procedures of statistics: a biometrical approach. McGraw-Hill, New York, N.Y.
17. Steers, E., E. L. Foltz, B. S. Graves, and J. Riden. 1959. An inocula replicating apparatus for routine testing of bacterial susceptibility to antibiotics. Antibiot. Chemother. (Basel) 9:307-311.
18. van Ogtrop, M. L., D. Andes, T. J. Stamstad, B. Conklin, W. J. Weiss, W. A. Craig and O. Vesga. 2000. In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria. Antimicrob. Agents Chemother. 44:943-949.